Session Information
Date: Thursday, June 8, 2017
Session Title: Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment
Session Time: 1:15pm-2:45pm
Location: Exhibit Hall C
Objective: To investigate the validity of telemedicine system in Parkinson’s disease(PD).
Background: PD patients may be difficult to visit the hospitals because of decline of activity of daily living (ADL) levels. Furthermore, there are few neurologists who is specialized in PD. Access to neurologists is considered an important factor that ameliorates management of the symptoms in PD.
In this study, we investigated the efficacy and safety of a video-based telemedicine system utilizing tablet device in PD.
Methods: We conducted a randomized cross-over trial comparing telemedicine period (regular bimonthly visits with intermediate video calls utilizing iPad mini®) to control period (regular bimonthly visits). Patients were randomized to receive either telemedicine period followed by control period, or control period followed by telemedicine period. Both periods were 6 months. The primary outcome measure was the Parkinson’s Disease Questionnaire (PDQ-39) summary index, which was measured at baseline, 6 months and 12 months. The secondary outcomes included the Unified Parkinoson’s Disease Rating Scale (UPDRS) part I-IV, Hoehn and Yahr Stage, Beck Depression Inventory (BDI). The visual analog questionnaires for satisfaction of the telemedicine system was also evaluated at 12 months.
Results: Ten patients were recruited and nine patients with PD completed the study periods. Average age at onset, average disease duration (year) and average Hoehn and Yahr stage were 53.7±5.9, 7.0±6.3, and 2.0±0.5, respectively. There were no significant differences between the two periods in PDQ-39 SI, as well as UPDRS part I, II, IV, Modified Hoehn and Yahr Stage, and BDI (P > .05). The participants rated the telemedicine system high scores. The number of extra hospital visit and phone call did not differ between two periods.
Conclusions: This study revealed that telemedicine system was well accepted. As this study did not show inferiority of telemedicine system for care of relatively mild PD, this system may be able to apply to care of advanced PD . Further studies are needed to reveal the validity of telemedicine system in advanced PD.
To cite this abstract in AMA style:
S. Sekimoto, G. Oyama, T. Hatano, F. Sasaki, R. Nakamura, T. Jo, Y. Shimo, N. Hattori. A prospective randomized cross-over study of telemedicine system in Parkinson’s disease [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/a-prospective-randomized-cross-over-study-of-telemedicine-system-in-parkinsons-disease/. Accessed May 21, 2025.« Back to 2017 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/a-prospective-randomized-cross-over-study-of-telemedicine-system-in-parkinsons-disease/